PDSB
PDS Biotechnology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Gap Up
Three Black Crows
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PDSB
Pds Biotechnology Corporation
A clinical-stage immunotherapy company that develops hospital-based novel therapies to treat acute life-threatening neurological conditions
Biological Technology
01/22/2009
10/01/2015
NASDAQ Stock Exchange
24
12-31
Common stock
303A College Road East, Princeton, NJ 08540
--
PDS Biotechnology Corporation was incorporated under the laws of the State of Delaware on January 22, 2009. The company is a clinical-stage biotechnology company focused on discovering, developing and seeking to commercialize novel hospital-based treatment options that transform treatment patterns and life-threatening management.
Earnings Call
Q2/2025
Estimate EPS-0.23
Actual EPS-0.21
Estimate Revenue--
Actual Revenue0
Contradictions Uncovered: Insights from the Latest VERSATILE Clinical Trials Earnings Call
Aug 13,2025 10:20
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.17
Actual EPS-0.19
Estimate Revenue--
Actual Revenue0
PDS Biotechnology's Q3 2025: Contradictions Emerge on VERSATILE-003 Patient Management, PFS Expectations, Study Design, and Funding Strategy
Nov 13,2025 10:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PDSB has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.17, missing expectations. The chart below visualizes how PDSB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
